OncoBayes2 (Q52525): Difference between revisions

From MaRDI portal
Created claim: source code repository (P339): https://github.com/cran/OncoBayes2, #quickstatements; #temporary_batch_1711029738451
Swh import (talk | contribs)
SWHID from Software Heritage
 
Property / Software Heritage ID
 
Property / Software Heritage ID: swh:1:snp:d9a2dc45a343cd68fc140be86cacebc6c0b79661 / rank
 
Normal rank
Property / Software Heritage ID: swh:1:snp:d9a2dc45a343cd68fc140be86cacebc6c0b79661 / qualifier
 
Property / Software Heritage ID: swh:1:snp:d9a2dc45a343cd68fc140be86cacebc6c0b79661 / qualifier
 
point in time: 17 August 2023
Timestamp+2023-08-17T00:00:00Z
Timezone+00:00
CalendarGregorian
Precision1 day
Before0
After0

Latest revision as of 02:33, 22 March 2024

Bayesian Logistic Regression for Oncology Dose-Escalation Trials
Language Label Description Also known as
English
OncoBayes2
Bayesian Logistic Regression for Oncology Dose-Escalation Trials

    Statements

    0 references
    0.8-8
    3 March 2023
    0 references
    0.4-4
    29 August 2019
    0 references
    0.5-3
    15 November 2019
    0 references
    0.5-4
    19 November 2019
    0 references
    0.5-8
    12 December 2019
    0 references
    0.6-0
    11 February 2020
    0 references
    0.6-3
    19 March 2020
    0 references
    0.6-4
    7 April 2020
    0 references
    0.6-5
    7 May 2020
    0 references
    0.7-0
    7 May 2021
    0 references
    0.8-1
    2 September 2021
    0 references
    0.8-2
    14 September 2021
    0 references
    0.8-4
    18 February 2022
    0 references
    0.8-5
    1 March 2022
    0 references
    0.8-6
    2 May 2022
    0 references
    0.8-7
    25 August 2022
    0 references
    0.8-9
    20 July 2023
    0 references
    0 references
    20 July 2023
    0 references
    Bayesian logistic regression model with optional EXchangeability-NonEXchangeability parameter modelling for flexible borrowing from historical or concurrent data-sources. The safety model can guide dose-escalation decisions for adaptive oncology Phase I dose-escalation trials which involve an arbitrary number of drugs. Please refer to Neuenschwander et al. (2008) <doi:10.1002/sim.3230> and Neuenschwander et al. (2016) <doi:10.1080/19466315.2016.1174149> for details on the methodology.
    0 references
    0 references
    0 references
    0 references
    0 references
    0 references
    0 references
    0 references
    0 references
    0 references
    0 references
    0 references
    0 references
    0 references
    0 references
    0 references
    0 references
    0 references
    0 references
    0 references
    0 references
    0 references
    0 references
    0 references
    0 references

    Identifiers